Seattle biotech BrainChild Bio has raised $116 million to advance an experimental CAR T cell therapy for DIPG, a rare and ...

Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly ...

BrainChild Bio has raised $116 million in Series A funding to advance its CAR T cell therapies for central nervous system ...

Funding will advance Phase 2 pivotal clinical trial for BCB-276 in an aggressive pediatric brain cancer, and support early pipeline programs for other CAR T cell therapies for pediatric and adult ...

BrainChild Bio’s lead asset BCB-276 is in pivotal development for diffuse intrinsic pontine glioma, a rare and fatal brain tumor that affects around 300 children in the U.S. every year.

SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous system (CNS), today ...

ILLUMINATE Phase 2 pivotal study will enroll patients at six leading pediatric oncology centers across the U.S.B7-H3-targeted autologous CAR T ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The Netflix series Brainchild explores the science behind the everyday — social media, germs, superheroes, dreams — and it’s hosted by Sahana Srinivasan, a talented actress and science communicator ...

What exactly are memories? How big is the universe? Do fish pee? "You're about to find out," promises Sahana Srinivasan in the trailer for Netflix's new science show "Brainchild." Likened to popular ...